Nearly 23 million people across the EU5 suffer from major depressive disorder. Generic availability of a growing number of therapies has improved patient access to antidepressants and loosened restrictions on off-label adjunctive use of atypical antipsychotics. New branded therapies will face increasing market access challenges as they compete for positioning in this crowded market. Clear demonstration of improved efficacy over standard-of-care comparators is necessary, though in some markets, safety or quality of life improvements are acceptable when accompanied by noninferior efficacy, and successfully targeting subpopulations or unmet treatment needs are additional keys to therapies securing favorable formulary placement and reimbursement terms.

Table of contents

  • Detailed, Expanded Analysis (EU5)
    • Actionable Recommendations to Optimize Market Access
      • Optimizing Market Access Opportunity for New MDD Therapies in the EU5
    • Successes and Stumbles
      • Successes Among MDD Therapies in the EU5
      • Stumbles Among MDD Therapies in the EU5
      • France: Reimbursement Successes and Stumbles
      • Germany: Reimbursement Successes and Stumbles
      • Italy: Reimbursement Successes and Stumbles
      • Spain: Reimbursement Successes and Stumbles
      • United Kingdom: Reimbursement Successes and Stumbles
    • Key Stakeholders in the Road to Market Access
      • France
      • Germany
      • Italy
      • Spain
      • United Kingdom
    • Key Market Access Roadblocks
      • France: Key Market Access Roadblocks
      • Germany: Key Market Access Roadblocks
      • Italy: Key Market Access Roadblocks
      • Spain: Key Market Access Roadblocks
      • United Kingdom: Key Market Access Roadblocks
    • Reimbursement Dynamics
      • France
        • France: Crucial HTA Criteria
        • France: P&R Drivers and Key HTA Considerations
        • France: HTA Review Details
        • France: Lessons Learned and Key Takeaways
        • France: Reimbursement Background
      • Germany
        • Germany: Crucial HTA Criteria
        • Germany: P&R Drivers and Key HTA Considerations
        • Germany: HTA Review Details
        • Germany: Lessons Learned and Key Takeaways
        • Germany: Reimbursement Background
      • Italy
        • Italy: Crucial HTA Criteria
        • Italy: P&R Drivers and Key HTA Considerations
        • Italy: HTA Review Details
        • Italy: Lessons Learned and Key Takeaways
        • Italy: Reimbursement Background
      • Spain
        • Spain: Crucial HTA Criteria
        • Spain: P&R Drivers and Key HTA Considerations
        • Spain: HTA Review Details
        • Spain: Lessons Learned and Key Takeaways
        • Spain: Reimbursement Background
      • United Kingdom
        • United Kingdom: Crucial HTA Criteria
        • United Kingdom: P&R Drivers and Key HTA Considerations
        • United Kingdom: HTA Review Details
        • United Kingdom: Lessons Learned and Key Takeaways
        • United Kingdom: Reimbursement Background
    • Pricing and Reimbursement, Policy, and Coverage: Impact on Prescribing
      • Prescriber Preferences for MDD
      • Impact of Payer Policy on Prescribing for MDD
      • Top Prescribing Drivers: MDD
    • Market Access Landscape for Emerging Therapies
      • Likely Impact of Emerging Therapies on MDD
      • Market Access Challenges for Emerging Therapies for MDD
      • Payer Opinion on Emerging Therapies for MDD
    • Methodology
      • Primary Research Design
      • Physician Demographics and Practice Setting
    • Appendix
      • Key Therapies for Major Depressive Disorder
        • Rexulti (Brexpiprazole)
        • ALKS-5461
      • Physician Survey Data

Author(s): Angela Sparrow, PhD

Angela Sparrow provides expert insight and authors primary market research and forecasting content as a member of the Central Nervous System and Ophthalmology Team. During her time with the company, Angela has extensively covered migraine, contributing to numerous reports while staying up-to-date on the latest trends and news. Additionally, she provides detailed responses to client inquiries and has authored content focused on psychiatric indications, including opioid addiction and depression, as well as neuropathic pain. Dr. Sparrow holds a in behavioral neuroscience from the University of North Carolina at Chapel Hill and a Bachelor’s degree from Northeastern University. Before joining DRG, she was a postdoctoral fellow at McLean Hospital, Harvard Medical School, studying the role of kappa opioid receptors in addiction and withdrawal-induced depression.

Related Reports

Unipolar Depression | Landscape & Forecast | Disease Landscape & Forecast

Unipolar depression’s very crowded generic therapy market makes it a challenge for branded agents to gain a strong foothold. SSRI...

View Details

Unipolar Depression | Access & Reimbursement | Detailed, Expanded Analysis (US) Major Depressive Disorder

Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies for the treatment of major depressive disorder (MDD

View Details

Unipolar Depression | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis

In the United States a plethora of pharmacological treatments from an array of drug classes are available to patients with major depressive disorder (MDD

View Details